Sir -I disagree with Greene's main conclusions. In my opinion, the main impediment in discussing areas of research other than our own is the knowledge that we do not know enough. While I am giving classes about CD4-gp120 interactions and CCR5/CXCR4 discrimination of HIV tropism, new receptors are being described and my knowledge seems completely outdated.
The 'information network' is so immense that we do not have time to read all about our narrow specialities, much less related areas, and still do our own research. And the pressure to publish is still increasing, the number of reviews published appears to me to be decreasing, and my ignorance of results from other areas of research stupefying.
Working in research I do not like being 'outdated' or simply wrong, so I avoid public statement of opinions. 
Vera Bongertz

Lab AIDS & Molecular
Duplications in nomenclature
Sir -The nomenclature of genes and proteins in molecular and developmental biology, as discussed in a recent leading article in Nature 1 , is often illogical and confusing. This problem is sometimes compounded when two proteins without any structural and functional relationship receive the same designation.
In a recent publication by Pan et al. 2 , for example, the authors describe the cloning and characterization of a new membrane-anchored chemokine and propose the name "neurotactin" for this type of molecule.
The term "neurotactin" was, however, used previously to describe a Drosophila membrane protein with an extracellular serine esterase-type protein domain which is dynamically expressed by neuroblasts and other tissues in the fly embryo 3, 4 . Drosophila neurotactin has no sequence or functional similarity to the molecule characterized by Pan et al. 2 . As a solution to such problems, journals should require the authors of manuscripts in which new names or terms are proposed to carry out a computer literature search.
In the case described above, a Medline search would have revealed the duplication and avoided possible confusion to some readers. Luckily, the CX3C membranebound chemokine described by Pan et al.
2 is identical to a molecule for which Bazan et al. 5 proposed the name "fractalkline", so an alternative designation is available.
